Q32 Bio Stock Analysis
| QTTB Stock | 1.88 0.03 1.62% |
Q32 Bio is undervalued with Real Value of 4.37 and Target Price of 12.0. The main objective of Q32 Bio stock analysis is to determine its intrinsic value, which is an estimate of what Q32 Bio is worth, separate from its market price. There are two main types of Q32 Bio's stock analysis: fundamental analysis and technical analysis.
The Q32 Bio stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Q32 Bio's ongoing operational relationships across important fundamental and technical indicators.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Q32 Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. Q32 Stock Analysis Notes
About 70.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 4.34. Q32 Bio had not issued any dividends in recent years. The entity had 1:18 split on the 26th of March 2024. To find out more about Q32 Bio contact Jodie Morrison at 781 999 0232 or learn more at https://www.q32bio.com.Q32 Bio Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Q32 Bio's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Q32 Bio or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Q32 Bio is way too risky over 90 days horizon | |
| Q32 Bio may become a speculative penny stock | |
| Q32 Bio appears to be risky and price may revert if volatility continues | |
| Q32 Bio has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (47.73 M) with loss before overhead, payroll, taxes, and interest of (48.15 M). | |
| Q32 Bio generates negative cash flow from operations | |
| Q32 Bio has a frail financial position based on the latest SEC disclosures | |
| About 70.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 161323 shares by Kalowski Lee of Q32 Bio at 16.82 subject to Rule 16b-3 |
Q32 Largest EPS Surprises
Earnings surprises can significantly impact Q32 Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-08-14 | 2023-06-30 | -0.5 | -0.61 | -0.11 | 22 | ||
2023-11-14 | 2023-09-30 | -0.43 | -0.57 | -0.14 | 32 | ||
2018-08-13 | 2018-06-30 | -0.33 | -0.16 | 0.17 | 51 |
Q32 Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 22.87 M.Q32 Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.52) | (0.54) | |
| Return On Capital Employed | (0.87) | (0.91) | |
| Return On Assets | (0.52) | (0.54) | |
| Return On Equity | (8.41) | (7.99) |
Management Efficiency
Q32 Bio has return on total asset (ROA) of (0.3595) % which means that it has lost $0.3595 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.9167) %, meaning that it created substantial loss on money invested by shareholders. Q32 Bio's management efficiency ratios could be used to measure how well Q32 Bio manages its routine affairs as well as how well it operates its assets and liabilities. As of August 23, 2025, Return On Tangible Assets is expected to decline to -0.54. In addition to that, Return On Capital Employed is expected to decline to -0.91. At present, Q32 Bio's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 801.1 K, whereas Non Current Assets Total are forecasted to decline to about 9.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.61 | 0.58 | |
| Tangible Book Value Per Share | 0.61 | 0.58 | |
| Enterprise Value Over EBITDA | 0.60 | 0.63 | |
| Price Book Value Ratio | 5.65 | 5.37 | |
| Enterprise Value Multiple | 0.60 | 0.63 | |
| Price Fair Value | 5.65 | 5.37 | |
| Enterprise Value | -27 M | -25.7 M |
Understanding the operational decisions made by Q32 Bio management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Technical Drivers
As of the 23rd of August, Q32 Bio owns the coefficient of variation of 1622.4, and Market Risk Adjusted Performance of (0.56). In connection with fundamental indicators, the technical analysis model allows you to check timely technical drivers of Q32 Bio, as well as the relationship between them.Q32 Bio Price Movement Analysis
The output start index for this execution was thirty-eight with a total number of output elements of twenty-three. The Double Exponential Moving Average indicator was developed by Patrick Mulloy. It consists of a single exponential moving average and a double exponential moving average. This indicator is more responsive to Q32 Bio changes than the simple moving average.
Q32 Bio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Q32 Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Q32 Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Q32 Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Q32 Bio Outstanding Bonds
Q32 Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Q32 Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Q32 bonds can be classified according to their maturity, which is the date when Q32 Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Q32 Bio Predictive Daily Indicators
Q32 Bio intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Q32 Bio stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Q32 Bio Forecast Models
Q32 Bio's time-series forecasting models are one of many Q32 Bio's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Q32 Bio's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Q32 Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Q32 Bio prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Q32 shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Q32 Bio. By using and applying Q32 Stock analysis, traders can create a robust methodology for identifying Q32 entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | 7.23 | 7.59 | |
| Operating Profit Margin | 6.53 | 6.86 | |
| Net Profit Margin | 7.27 | 7.64 | |
| Gross Profit Margin | 0.98 | 0.65 |
Current Q32 Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Q32 analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Q32 analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 12.0 | Buy | 3 | Odds |
Most Q32 analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Q32 stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Q32 Bio, talking to its executives and customers, or listening to Q32 conference calls.
Q32 Stock Analysis Indicators
Q32 Bio stock analysis indicators help investors evaluate how Q32 Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Q32 Bio shares will generate the highest return on investment. By understating and applying Q32 Bio stock analysis, traders can identify Q32 Bio position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 31.3 M | |
| Long Term Debt | 9.6 M | |
| Common Stock Shares Outstanding | 9.7 M | |
| Total Stockholder Equity | 5.7 M | |
| Total Cashflows From Investing Activities | 19.9 M | |
| Tax Provision | 21 K | |
| Property Plant And Equipment Net | 7.1 M | |
| Cash And Short Term Investments | 78 M | |
| Cash | 78 M | |
| Accounts Payable | 3 M | |
| Net Debt | -59.1 M | |
| 50 Day M A | 1.8911 | |
| Total Current Liabilities | 16.5 M | |
| Other Operating Expenses | 66.1 M | |
| Non Current Assets Total | 10.5 M | |
| Non Currrent Assets Other | 763 K | |
| Stock Based Compensation | 4.4 M |
Complementary Tools for Q32 Stock analysis
When running Q32 Bio's price analysis, check to measure Q32 Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Q32 Bio is operating at the current time. Most of Q32 Bio's value examination focuses on studying past and present price action to predict the probability of Q32 Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Q32 Bio's price. Additionally, you may evaluate how the addition of Q32 Bio to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |